• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Lebar Daun Berhad

  • ID: 641563
  • December 2014
  • 55 Pages
  • Wright Investors Service

A textual analysis of the financial results for Lebar Daun Berhad compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business description of the company, including contact information, senior officers and Wright Quality Rating analyses is also provided.

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio tables (Accounting, Asset Utilization, Employee Efficiency, Fixed Charges Coverage, Leverage Analysis, Liquidity Analysis, Per-share Data and Profitability Analysis) and proprietary Wright Quality Rating analyses tables. The Wright Quality Rating, a measure of corporate risk, examines the liquidity of the stock, financial strength, profitability and corporate growth characteristics of Lebar Daun Berhad. There is a textual review of the financial results of Lebar Daun Berhad versus Lien Hoe Corporation Berhad, A & M Realty Berhad and Pasdec Holdings Berhad. The comparative analysis of these companies compares Sales (sales, sales growth and READ MORE >

Note: Product cover images may vary from those shown

Company Fundamentals
- Company Profile
- Comparative Business Analysis
- Summary Analysis per Share
- Sales Analysis
- Price Analysis
- Earnings and Dividends Analysis

Financial Statement Analyses
- Balance Sheet - Common Size
- Balance Sheet - Year-Year Percent Change
- Balance Sheet - Five-Year Averages
- Income Statement - Common Size
- Income Statement - Year-Year Percent Change
- Income Statement - Five-Year Averages
- Sources of Capital

Financial Ratio Analyses
- Accounting Ratios
- Asset Utilization
- Employee Efficiency
- Fixed Charges Coverage
- Leverage Analysis
- Liquidity Analysis
- Per-Share Data
- Profitability Analysis

Wright Quality Rating Analyses
- Investment Acceptance
- Financial Strength
- Profitability and Stability
- Corporate Growth

Note: Product cover images may vary from those shown

Tebrau Teguh Berhad, Ibraco Berhad and Sycal Ventures Berhad

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

  • LEBAR DAUN Bhd Acquisition Manual - Product Thumbnail Image LEBAR DAUN Bhd Acquisition Manual

    LEBAR DAUN Bhd Acquisition Manual

    • Language: English
    • Published: April 2015
  • Lien Hoe Corporation Berhad - Product Thumbnail Image

    Lien Hoe Corporation Berhad

    • Language: English
    • 55 Pages
    • Published: March 2015
    FROM
  • Sycal Ventures Berhad - Product Thumbnail Image

    Sycal Ventures Berhad

    • Language: English
    • 55 Pages
    • Published: March 2015
    FROM
  • Oriental Interest Berhad - Product Thumbnail Image

    Oriental Interest Berhad

    • Language: English
    • 37 Pages
    • Published: March 2015
    FROM
  • Magna Prima Berhad - Product Thumbnail Image

    Magna Prima Berhad

    • Language: English
    • 55 Pages
    • Published: March 2015
    FROM
  • Pasdec Holdings Berhad - Product Thumbnail Image

    Pasdec Holdings Berhad

    • Language: English
    • 55 Pages
    • Published: March 2015
    FROM
  • Ibraco Berhad - Product Thumbnail Image

    Ibraco Berhad

    • Language: English
    • 37 Pages
    • Published: March 2015
    FROM
  • MBS Inc - Product Thumbnail Image

    MBS Inc

    • Language: English
    • 55 Pages
    • Published: March 2015
    FROM
  • Crowell Development Corp - Product Thumbnail Image

    Crowell Development Corp

    • Language: English
    • 56 Pages
    • Published: April 2015
    FROM
  • Ken Holdings Berhad - Product Thumbnail Image

    Ken Holdings Berhad

    • Language: English
    • 55 Pages
    • Published: April 2015
    FROM

Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.